AGPS

AGPS (alkylglyceronephosphate synthase) is the peroxisomal enzyme that catalyzes a committed step in ether lipid biosynthesis, and its activity governs the cellular pool of structural and signaling ether lipids that sustain cancer cell survival and tumor growth (PMID:23980144). Within the peroxisome, AGPS is imported by PEX7 and functions in partnership with GNPAT on the luminal membrane surface, where its presence is required for full GNPAT activity and substrate channeling into plasmalogen synthesis; AGPS mutations that disrupt this partnership cause rhizomelic chondrodysplasia punctata type 3 (RCDP3) (PMID:21990100). In mice, hypomorphic disruption that deletes the FAD enzymatic domain and complete knockout both deplete ether lipids and produce cataracts, male sterility, and substantial embryonic lethality, establishing AGPS as essential for development, lens fiber, and spermatogenic cell function (PMID:21353609, PMID:25197626). In cancer, loss of AGPS lowers oncogenic signaling lipids including LPA, LPAe, and prostaglandins, attenuating LPA- and EP-receptor-driven PI3K/AKT signaling and multidrug-resistance gene expression, while pharmacological inhibitors that bind the AGPS active site selectively reduce ether lipids and impair cancer cell survival and migration (PMID:23980144, PMID:24815474, PMID:26322624). AGPS is regulated post-translationally: TrkA phosphorylates AGPS at Y451 to promote MDM2-mediated ubiquitination and proteasomal degradation, and blocking this axis raises AGPS levels and sensitizes prostate cancer cells to ferroptosis (PMID:38200609). Transcriptionally, a MEIS3/AGPS/NF-κB axis drives oncogenic phenotypes in esophageal squamous cell carcinoma (PMID:41950565).

1. 2011 Medium

   Established how AGPS is delivered to its site of action and that it does not act alone, defining the peroxisomal import route and the enzymatic partnership underlying plasmalogen synthesis.

   Evidence Patient-derived cell-line protein quantification, structural modeling of AGPS mutations, and transcript analysis comparing AGPS and GNPAT

   PMID:21990100

   Open questions at the time

   • Substrate channeling inferred from protein-level interdependence rather than reconstituted enzymatic assay
   • Stoichiometry and structural basis of the AGPS–GNPAT complex not resolved
2. 2011 High

   Demonstrated in vivo that AGPS enzymatic activity is required for ether lipid production and identified the organismal consequences of its loss, linking the FAD domain to lens and spermatogenic phenotypes.

   Evidence Genetic mapping, transcript characterization, lipid mass spectrometry, and histology in hypomorphic bs2 mice

   PMID:21353609

   Open questions at the time

   • Hypomorphic allele leaves residual function, complicating null interpretation
   • Mechanism linking ether lipid depletion to specific lens/testis cell pathology not defined
3. 2013 High

   Connected AGPS-dependent ether lipid synthesis to oncogenic lipid signaling, showing that AGPS controls levels of LPA, LPAe, and prostaglandins required for cancer cell survival and tumor growth.

   Evidence siRNA/shRNA ablation across multiple cancer cell lines and xenografts with lipidomic profiling

   PMID:23980144

   Open questions at the time

   • Does not establish which downstream lipid species is rate-limiting for the phenotype
   • Direct receptor-level signaling consequences not measured here
4. 2014 High

   Confirmed AGPS is required for normal development using a complete knockout, extending the hypomorphic phenotypes to embryonic lethality.

   Evidence KOMP knockout mouse, survival analysis, and histological phenotyping

   PMID:25197626

   Open questions at the time

   • Cause of embryonic lethality at the cellular/pathway level not determined
   • Tissue-autonomous requirements not dissected
5. 2014 Medium

   Linked AGPS to chemoresistance by mapping lipid changes to PI3K/AKT signaling and multidrug-resistance gene expression in resistant tumor cells.

   Evidence siRNA knockdown in chemoresistant glioma and hepatic carcinoma lines with lipid measurement, signaling Western blots, and proliferation/apoptosis assays

   PMID:24815474

   Open questions at the time

   • Single-lab study with two cell lines
   • Causality between specific lipids and MDR gene regulation not isolated
6. 2015 High

   Validated AGPS as a druggable enzyme by identifying active-site-binding small molecules that phenocopy genetic ablation, establishing therapeutic tractability.

   Evidence Small-molecule screen, structural characterization of inhibitor binding, ether lipid profiling, and viability/migration assays in cancer cells

   PMID:26322624

   Open questions at the time

   • Inhibitor selectivity and potency in vivo not established here
   • Full enzyme structure with bound substrate not reported
7. 2021 Medium

   Identified HNRNPK as an AGPS interactor that can rescue AGPS-silencing phenotypes, introducing a possible compensatory or downstream node.

   Evidence Co-immunoprecipitation, mass spectrometry, confocal co-localization, and rescue in glioma cells

   PMID:34621897

   Open questions at the time

   • Reported nuclear co-localization of a peroxisomal enzyme with an RNA-binding protein is biologically unusual and not mechanistically explained
   • Single lab; functional relationship to ether lipid synthesis unclear
8. 2024 High

   Defined post-translational control of AGPS, showing TrkA-mediated Y451 phosphorylation drives MDM2-dependent proteasomal degradation and links AGPS stability to ferroptosis sensitivity.

   Evidence Co-IP, in vitro GST pull-down, label-free MS, Y451 site-directed mutagenesis, and prostate cancer xenografts with larotrectinib

   PMID:38200609

   Open questions at the time

   • Mechanistic link between AGPS levels and ferroptosis not fully resolved
   • Whether degradation regulates ether lipid flux quantitatively not measured
9. 2026 Medium

   Established transcriptional regulation of AGPS through an allele-specific MEIS3 binding event, defining a MEIS3/AGPS/NF-κB oncogenic axis in ESCC.

   Evidence CUT&Tag-qPCR, EMSA, RNA interference, xenografts, and transcriptomic profiling

   PMID:41950565

   Open questions at the time

   • Single-lab study
   • Mechanism by which AGPS activates NF-κB not biochemically defined

• How AGPS's peroxisomal enzymatic output is mechanistically coupled to nuclear/transcriptional partners (HNRNPK, NF-κB) and how its post-translational and transcriptional regulation integrate to control ether lipid flux in vivo remain unresolved.
• No unified model linking ether lipid production to nuclear signaling effects
• Substrate-bound enzyme structure and catalytic mechanism not reported in the corpus